Vitamin K antagonists (VKA) are a group of substances that reduce blood clotting by reducing the action of vitamin K. The term "vitamin K antagonist" is technically a misnomer, as the drugs do …

2020年6月15日 · DOACs are relatively new agents demonstrating superiority or noninferiority to prior standards of care, anticoagulation with vitamin K antagonists (VKA; ie, warfarin), or …

This topic review discusses the biology, mechanism of action, and factors that modulate INR control during anticoagulation with a VKA. Separate topics discuss: Warfarin administration – …

2024年7月17日 · Recent data indicate that it is safe to use a combination of a VKA and clopidogrel instead of triple antithrombotic therapy (VKA, ASA, and clopidogrel). An …

In patients beginning vitamin K antago-nist (VKA) therapy, we recommend the initia-tion of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most …

When administered in doses that increase the INR to 2.0–3.0, vitamin K antagonists (VKAs) effectively prevent postoperative VTE in patients in all risk categories. VKAs can be given …

VKAs exert their anticoagulant effect by interfering with the cyclic interconversion of vitamin K and its 2,3 epoxide (vitamin K epoxide), modulating the γ-carboxylation of glutamic acid residues...

In patients beginning vitamin K antagonist (VKA) therapy, we recommend the initiation of oral anticoagulation with doses between 5 mg and 10 mg for the first 1 or 2 days for most …

Patient self-management (PSM) of vitamin K antagonists (VKA) seems a very promising model of care for oral anticoagulation in terms of efficacy and safety. In comparison with other …

It describes the antithrombotic effect of the VKAs, the monitoring of anticoagulation intensity, and the clinical applications of VKA therapy and provides specific management recommendations. …